Scholarlink

Study Objectives: <p>Central sleep apnea (CSA) is a sleep disorder characterized by instability in the respiratory center’s function, leading to an excessive ventilatory response. The most effective treatment for these patients is adaptive servoventilation (ASV). We hypothesize that individuals with CSA may exhibit hyperresponsiveness of the respiratory center, and ASV treatment could normalize its function. We aimed to measure the ventilatory response to hypercapnia and its relationship with the outcomes following ASV treatment.</p> Methods: <p>A prospective study with repeated measurements was conducted on patients with CSA treated with ASV. A ventilatory response to a hypercapnia test was performed using p0.1/pEtCO<sub>2</sub> determinations: a first determination at the time of inclusion and a second one after at least 6 months of ASV treatment. We used the Pearson correlation test and the comparison of means (<i>t</i> test) for independent and paired variables for statistical analysis. A p0.1/pEtCO<sub>2</sub> value of 0.43 cmH<sub>2</sub>O/mmHg was considered the reference value.</p> Results: <p>We analyzed 46 participants, 82% male. The apnea-hypopnea index was 47 events/h (23), and the central apnea-hypopnea index was 27 events/h (12). The initial p0.1/pEtCO<sub>2</sub> was 0.48 (standard deviation: 0.24) cmH<sub>2</sub>O/mmHg, significantly higher than the reference value (<i>P</i> = .02). After ASV treatment, 63% of participants had a normalized p0.1/pEtCO<sub>2</sub>, which decreased to 0.37 (standard deviation: 0.23) cmH<sub>2</sub>O/mmHg and was significantly lower than the initial value (<i>P</i> = .015) and comparable to the reference value (<i>P</i> = .26). CSA secondary to opioid use had a substantially lower p0.1/pEtCO<sub>2</sub>: 0.27 cmH<sub>2</sub>O/mmHg (standard deviation: 0.11; <i>P</i> = .021).</p> Conclusions: <p>Ventilatory response to hypercapnia in patients with CSA and ASV treatment could differentiate phenotypes and impact therapeutic decisions.</p> Citation: <p>Posada IM-G, Álvarez RF, Ortiz Reyes A, et&#xa0;al. Respiratory center function in patients under adaptive servoventilation: etiology and outcome. <i>J Clin Sleep Med</i>. 2025;21(9):1539–1545.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Respiratory center function in patients under adaptive servoventilation: etiology and outcome

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Isabel Martinez-Gonzalez Posada,
  • Ramón Fernández Álvarez,
  • Andres Ortiz Reyes,
  • Marina Acebo Castro,
  • Ines Ruiz Alvarez,
  • Pablo Lozano Cuesta,
  • Claudia Madrid Carvajal,
  • Maria Vazquez López,
  • Marta Garcia Clemente,
  • Gemma Rubinos Cuadrado

摘要

Study Objectives:

Central sleep apnea (CSA) is a sleep disorder characterized by instability in the respiratory center’s function, leading to an excessive ventilatory response. The most effective treatment for these patients is adaptive servoventilation (ASV). We hypothesize that individuals with CSA may exhibit hyperresponsiveness of the respiratory center, and ASV treatment could normalize its function. We aimed to measure the ventilatory response to hypercapnia and its relationship with the outcomes following ASV treatment.

Methods:

A prospective study with repeated measurements was conducted on patients with CSA treated with ASV. A ventilatory response to a hypercapnia test was performed using p0.1/pEtCO2 determinations: a first determination at the time of inclusion and a second one after at least 6 months of ASV treatment. We used the Pearson correlation test and the comparison of means (t test) for independent and paired variables for statistical analysis. A p0.1/pEtCO2 value of 0.43 cmH2O/mmHg was considered the reference value.

Results:

We analyzed 46 participants, 82% male. The apnea-hypopnea index was 47 events/h (23), and the central apnea-hypopnea index was 27 events/h (12). The initial p0.1/pEtCO2 was 0.48 (standard deviation: 0.24) cmH2O/mmHg, significantly higher than the reference value (P = .02). After ASV treatment, 63% of participants had a normalized p0.1/pEtCO2, which decreased to 0.37 (standard deviation: 0.23) cmH2O/mmHg and was significantly lower than the initial value (P = .015) and comparable to the reference value (P = .26). CSA secondary to opioid use had a substantially lower p0.1/pEtCO2: 0.27 cmH2O/mmHg (standard deviation: 0.11; P = .021).

Conclusions:

Ventilatory response to hypercapnia in patients with CSA and ASV treatment could differentiate phenotypes and impact therapeutic decisions.

Citation:

Posada IM-G, Álvarez RF, Ortiz Reyes A, et al. Respiratory center function in patients under adaptive servoventilation: etiology and outcome. J Clin Sleep Med. 2025;21(9):1539–1545.